| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT02122081) | Sumithira Vasu | 2015-07-27 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02299518) | Alice Mims | 2015-05-18 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02316964) | Sumithira Vasu | 2015-04-21 |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (NCT01849276) | Northwestern University | 2015-03-11 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02049801) | Bruno C. Medeiros | 2014-12-01 |
| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT02071901) | Case Comprehensive Cancer Center | 2014-08-14 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02029417) | Roswell Park Cancer Institute | 2014-07-01 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML (NCT02094794) | City of Hope Medical Center | 2014-05-12 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02030405) | Steven E. Coutre | 2014-03-01 |
| CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02019069) | Rondeep Brar | 2014-02-03 |
| AML Therapy With Irradiated Allogeneic Cells (NCT02105116) | Rutgers, The State University of New Jersey | 2014-02-01 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01904643) | Stanford University | 2014-02-01 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (NCT01798901) | Alison Walker | 2013-09-17 |
| Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01876953) | City of Hope Medical Center | 2013-09-13 |
| Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (NCT01872819) | University of Washington | 2013-08-02 |
| Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy (NCT01869114) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-07-08 |
| Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia (NCT01869777) | Wake Forest University Health Sciences | 2013-07-01 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01707004) | University of Wisconsin, Madison | 2013-05-16 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01831232) | Fred Hutchinson Cancer Center | 2013-05-01 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01835288) | Stanford University | 2013-05-01 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01820624) | Paolo Caimi, MD | 2013-04-30 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01839916) | University of Chicago | 2013-04-04 |
| Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01822015) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-03-15 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (NCT01801046) | University of Southern California | 2013-03-06 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01768897) | Wake Forest University Health Sciences | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT01519596) | Wake Forest University Health Sciences | 2012-10-01 |
| Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (NCT01607645) | Fred Hutchinson Cancer Center | 2012-07-01 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01839240) | University of Chicago | 2012-06-06 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT01550185) | Roswell Park Cancer Institute | 2012-05-01 |
| Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (NCT01548911) | Wake Forest University Health Sciences | 2012-05-01 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (NCT01523223) | Robert Lowsky | 2012-01-01 |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (NCT01842139) | University of Chicago | 2011-12-05 |
| Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (NCT01521936) | Roswell Park Cancer Institute | 2011-12-01 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (NCT01555268) | Roswell Park Cancer Institute | 2011-10-31 |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (NCT01564277) | Roswell Park Cancer Institute | 2011-09-29 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01342887) | Fred Hutchinson Cancer Center | 2011-04-01 |
| Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01349972) | National Cancer Institute (NCI) | 2011-04-01 |
| Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01246622) | Roswell Park Cancer Institute | 2011-02-07 |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02085408) | ECOG-ACRIN Cancer Research Group | 2011-02-04 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy (NCT01235572) | Fred Hutchinson Cancer Center | 2010-12-01 |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447) | National Cancer Institute (NCI) | 2010-10-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS (NCT01141725) | Fred Hutchinson Cancer Center | 2010-09-01 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (NCT01174888) | Alison Walker | 2010-08-01 |
| Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm (NCT01101880) | University of Washington | 2010-08-01 |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (NCT01175785) | Nohla Therapeutics, Inc. | 2010-08-01 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT01127009) | Case Comprehensive Cancer Center | 2010-07-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01076270) | Fred Hutchinson Cancer Center | 2010-06-01 |
| Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant (NCT01083706) | Fred Hutchinson Cancer Center | 2010-04-01 |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (NCT01031368) | Nohla Therapeutics, Inc. | 2009-12-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML (NCT00895934) | National Cancer Institute (NCI) | 2009-05-01 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (NCT00860574) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease (NCT00863434) | University of Washington | 2009-02-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02144675) | Rutgers, The State University of New Jersey | 2009-01-01 |
| Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS (NCT00839982) | Fred Hutchinson Cancer Center | 2008-11-01 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00795002) | National Cancer Institute (NCI) | 2008-11-01 |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00634244) | National Cancer Institute (NCI) | 2008-10-01 |
| Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00742625) | National Cancer Institute (NCI) | 2008-09-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia (NCT00703300) | National Cancer Institute (NCI) | 2008-06-01 |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00475150) | National Cancer Institute (NCI) | 2008-05-01 |
| Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00673153) | Fred Hutchinson Cancer Center | 2008-03-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia (NCT00602771) | National Cancer Institute (NCI) | 2008-01-01 |
| Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00602225) | University of Washington | 2007-12-01 |
| Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer (NCT00540995) | City of Hope Medical Center | 2007-06-11 |
| Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00492401) | National Cancer Institute (NCI) | 2007-05-01 |
| MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00462605) | National Cancer Institute (NCI) | 2007-04-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia (NCT00470197) | National Cancer Institute (NCI) | 2007-04-01 |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia (NCT00459212) | National Cancer Institute (NCI) | 2007-03-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00407966) | National Cancer Institute (NCI) | 2006-10-01 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia (NCT00352365) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases (NCT00357708) | National Cancer Institute (NCI) | 2006-06-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| PXD101 in Treating Patients With Acute Myeloid Leukemia (NCT00357032) | National Cancer Institute (NCI) | 2006-05-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes (NCT00331513) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (NCT00275080) | National Cancer Institute (NCI) | 2006-02-01 |
| Vorinostat in Treating Patients With Acute Myeloid Leukemia (NCT00305773) | National Cancer Institute (NCI) | 2006-01-01 |
| Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (NCT00322101) | Fred Hutchinson Cancer Center | 2006-01-01 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia (NCT00301769) | National Cancer Institute (NCI) | 2005-12-01 |
| 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (NCT00301938) | National Cancer Institute (NCI) | 2005-12-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |